EVIDENT (Evidence-Based Validation & Innovation for Rapid Therapeutics)
Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)Washington, DC, 20005, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT (AN13)

Original Source

https://sam.gov/workspace/contract/opp/122aec725a09476e87b7cad91afe79ee/view
Timeline
    Description

    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is initiating the Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) initiative to fund innovative solutions that align with HHS and ARPA-H objectives. This initiative aims to efficiently support research and development in the field of behavioral health, particularly focusing on rapid therapeutic innovations. The Proposers’ Day, scheduled for December 10, 2025, will provide an opportunity for interested parties to learn more about the technical areas of the EVIDENT initiative and to engage with ARPA-H and Advanced Technology International (ATI). For additional information and registration details, interested parties are encouraged to refer to the provided links.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    EVIDENT (Evidence-Based Validation & Innovation for Rapid Therapeutics)
    Currently viewing
    Special Notice
    Similar Opportunities
    Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO). This initiative aims to gather innovative solutions that address future healthcare challenges, focusing on groundbreaking research in areas such as maternal/fetal medicine, genetic therapies, chronic diseases, and mental health, while excluding proposals for incremental advances or clinical trials. Proposers are required to submit a Solution Summary for initial feedback, followed by a detailed proposal that adheres to updated administrative and national policy requirements, including compliance with ethical research guidelines and research security disclosures. Interested parties should submit their proposals via the designated ARPA-H portal, with specific deadlines and further details available through the provided links.
    Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting innovative solutions aimed at enhancing the healthspan and health outcomes of Americans by focusing on proactive health measures. The Proactive Health Office (PHO) seeks proposals that address population-level improvements in disease prevention, early detection methods, and system-level innovations for effective health delivery, emphasizing revolutionary advances rather than incremental improvements. This opportunity is critical for fostering advancements in public health and requires adherence to specific administrative and national policy guidelines, including intellectual property rights and research security measures. Interested parties must submit a Solution Summary by March 5, 2029, and can find further details and submission links at https://solutions.arpa-h.gov, with inquiries directed to the same site.
    Autonomous Interventions and Robotics (AIR) Advanced Research Projects Agency for Health (ARPA-H)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is seeking proposals for its Autonomous Interventions and Robotics (AIR) program, which aims to advance autonomous robotic surgery technologies. This initiative focuses on two technical areas: Autonomous Endovascular Robotics, which includes developing robotic systems for endovascular procedures and creating a simulation environment, and Microbots, which targets the development of untethered, autonomous microbots for various interventional procedures. The program is structured over a five-year timeline with specific phases and milestones, emphasizing collaboration with the FDA for regulatory approval. Interested parties are encouraged to attend a Proposers’ Day on December 16, 2025, in Washington, DC, to learn more about the program and network with potential collaborators. For further inquiries, contact the AIR Program at AIR@ARPA-H.GOV.
    Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO). This opportunity invites submissions that address systemic challenges in healthcare and public health by leveraging innovative technologies to improve care quality, efficacy, and accessibility. Proposals will be evaluated based on scientific merit, alignment with ARPA-H's mission, proposer capabilities, and cost, with a focus on open-source intellectual property and compliance with research regulations. Interested parties must submit solution summaries and proposals via the designated ARPA-H portal, with the closing date for submissions set for March 5, 2029. For further inquiries, proposers can reach out through the same portal.
    Independent Validation and Verification (IV&V) Services for the REACT Program
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is seeking independent validation and verification (IV&V) services for its Resilient Extended Automatic Cell Therapies (REACT) program. The primary objective is to ensure the standardization and reproducibility of engineered cell lines used in developing wireless implantable medical devices, specifically the "Living Pharmacy" for therapeutic delivery and the "Living Sentinel" for disease tracking. These services are crucial for scaling manufacturing capabilities and aligning with regulatory standards, ultimately facilitating the commercialization of these health care devices. Proposals are due by January 5, 2026, with the contract covering a period from February 23, 2026, to August 22, 2028, and interested parties can contact Larin Harris at larim.harris@arpa-h.gov or Clare Sanchez at clare.sanchez@arpa-h.gov for further information.
    Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Innovative Solutions Opening (ISO) under the Scalable Solutions Office (SSO). This initiative aims to develop innovative solutions that enhance healthcare access, affordability, and distribution, particularly in underserved communities, while addressing challenges in biomanufacturing and health technology distribution. The solicitation is open until March 5, 2029, and encourages submissions from academia, non-profits, and for-profit entities, with multiple awards anticipated as Other Transactions. Interested parties must submit a Solution Summary for initial feedback before proceeding with a full proposal, adhering to strict guidelines on intellectual property, research security, and cost proposal requirements. For further details, proposers can reach out through the designated submission portals and must ensure compliance with the updated administrative and national policy requirements outlined in the solicitation documents.
    Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the "Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)" program. This initiative aims to accelerate the development of innovative precision genetic medicines (PGMs) to treat hereditary rare diseases, focusing on creating integrated platforms that address technical and real-world challenges in genetic medicine. Proposals must include a solution summary, a PowerPoint presentation, and a detailed Gantt chart, with key deadlines set for October 31, 2025, for solution summaries and December 22, 2025, for PowerPoint submissions. Interested parties can contact the THRIVE Program at THRIVE@arpa-h.gov for further information.
    Special Notice for BioStabilization Systems (BoSS)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is announcing a Special Notice for the BioStabilization Systems (BoSS) program, with a Proposers’ Day scheduled for January 29, 2026. This initiative aims to revolutionize the storage and transport of biological medicines by developing technologies that eliminate the need for ultra-cold conditions, and it seeks performer teams for breakthrough cell stabilization technologies and bioprocessing solutions, as well as an Independent Verification and Validation (IV&V) partner. The program is structured in three phases over four years, culminating in the transition of successful technologies to commercial partners, and encourages collaboration among teams. Interested parties can find more information and registration details on the ARPA-H website and should direct inquiries to the provided contact email, although it is noted that the email address should not be used for direct communication.
    Autonomous Interventions and Robotics (AIR) Advanced Research Projects Agency for Health (ARPA-H)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Autonomous Interventions and Robotics (AIR) program, aimed at advancing autonomous robotic surgery technologies. This initiative focuses on two key technical areas: autonomous endovascular robotics, which includes developing systems for procedures such as thrombectomy and embolization, and the creation of untethered microbots for various clinical applications. The program is critical for enhancing medical interventions and is structured over a five-year timeline, with specific milestones for development and testing phases. Interested parties, including universities, non-profits, and businesses, must submit their proposals by March 30, 2026, with a preliminary Solution Summary due by January 26, 2026. For further inquiries, contact the AIR Program at AIR@ARPA-H.GOV.
    GENETIC MEDICINES AND INDIVIDUALIZED MANUFACTURING FOR EVERYONE (GIVE)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. This initiative aims to revolutionize the biomanufacturing of RNA-based genetic medicines by fostering innovations in automated RNA manufacturing and integrated quality control, ultimately enabling rapid, cost-effective, and localized production in non-GMP environments. Interested parties must submit solution summaries by December 19, 2025, with full proposals due by February 27, 2026, and are encouraged to participate in a Proposers’ Day on November 13, 2025, for further insights. For additional information, please refer to the program's website or contact the designated email address.